Claims for Patent: 5,756,264

Summary for Patent: 5,756,264

Title:	Expression vector systems and method of use
Abstract:	This invention relates to gene therapy by using vectors which encode stable MRNA and methods of using such vectors. In particular, this invention relates to vectors which establish controlled expression of recombinant genes within tissues at certain levels. The vector includes a 5\' flanking region which includes necessary sequences for expression of a nucleic acid cassette, a 3\' flanking region including a 3\' UTR and/or 3\' NCR which stabilizes mRNA expressed from the nucleic acid cassette, and a linker which connects the 5\' flanking region to a nucleic acid sequence. The linker has a position for inserting a nucleic acid cassette. The linker does not contain the coding sequence of a gene that the linker is naturally associated with. The 3\' flanking region is 3\' to the position for inserting the nucleic acid cassette. The expression vectors of the present invention can also be regulated by a regulatory system and/or constructed with a coating.
Inventor(s):	Schwartz; Robert J. (Houston, TX), DeMayo; Franco J. (Houston, TX), O\'Malley; Bert W. (Houston, TX)
Assignee:	Baylor College of Medicine (Houston, TX)
Application Number:	08/209,846
Patent Claims:	1. A vector for expression of a nucleic acid sequence in tissue, comprising: a 5' flanking region including necessary sequences for expression of a nucleic acid cassette; a linker connecting said 5' flanking region to a nucleic acid, said linker having a position for inserting said nucleic acid cassette, wherein said linker lacks the coding sequence of a gene with which it is naturally associated; and a 3' flanking region including a eukaryotic 3'UTR and/or a eukaroyotic 3'NCR which stabilizes MRNA expressed from said nucleic acid cassette, wherein said 3' flanking region is 3' to said position for inserting said nucleic acid cassette. 2. The vector of claim 1, wherein said vector further comprises a nucleic acid cassette. 3. The vector of claims 1 or 2, wherein said 5' flanking region and/or said 3' flanking region regulates expression of said nucleic acid cassette predominately in a specific tissue. 4. The vector of claim 3, wherein said specific tissue is myogenic. 5. The vector of claims 1 or 2, wherein said 3' UTR corresponds to nucleotide 2060 to nucleotide 2331 of the chicken skeletal .alpha.-actin gene. 6. The vector of claims 1 or 2, wherein said 3' UTR and said 3' NCR extend approximately 2.3 Kb from nucleotide 2060 of the chicken skeletal .alpha.-actin gene. 7. The vector of claims 1 or 2, wherein said 3' UTR and/or said 3' NCR are derived from a gene selected from the group consisting of skeletal .alpha.-actin gene, fast myosin light chain 1 gene, myosin light chain 1/3 gene, myosin heavy chain gene, tropinin T gene and muscle creatinine kinase gene. 8. The vector of claims 1 or 2 wherein said 5' flanking region includes a promoter, a TATA box, a Cap site and a first intron and intron/exon boundary in appropriate relationship for expression of said nucleic acid cassette. 9. The vector of claim 8, wherein said 5' flanking region further comprises a 5' mRNA leader sequence inserted between said promoter and said nucleic acid cassette. 10. The vector of claims 1 or 2, further comprising a coating to enhance cellular uptake. 11. The vector of claim 10, wherein said coating comprises: a DNA initiation complex; and histones. 12. The vector of claim 11, wherein said DNA initiation complex comprises: a serum response factor; a serum response element, wherein said serum response factor interacts with said serum response element within a promoter region of said vector; 5 a transcription initiation factor; and a transregulatory factor; wherein said transcription initiation factor and said transregulatory factor interact with said serum response factor and said promoter to form a stable complex. 13. The vector of claims 1 or 2, further comprising a regulatory system for regulating the expression of said nucleic acid cassette. 14. The vector of claim 13, wherein said regulatory system comprises: a chimeric trans-acting regulatory factor located within a promoter sequence of said vector, wherein said chimeric trans-acting regulatory factor incorporates a serum response factor with a DNA binding domain sequence of a receptor; an agent capable of binding to said DNA binding domain sequence of said receptor; and a transactivation domain within said serum response factor, wherein said transactivation domain regulates transcription when said agent binds said DNA binding domain sequence of said receptor. 15. The vector of claim 14 wherein said DNA binding domain sequence of said receptor is selected from the group consisting of vitamin, steroid, thyroid, orphan, hormone, retinoic acid, thyroxine or GAL4 receptors. 16. The vector of claim 14 wherein said promoter sequence is an a-actin promoter sequence, said DNA binding domain sequence of said receptor is from a Vitamin D receptor and said agent is Vitamin D. 17. A vector containing a regulatory system for 5 expression of a nucleic acid sequence in tissue, comprising: a first functional unit comprising a promoter, a nucleic acid sequence coding for a receptor and a 3' UTR and/or a 3'NCR; an agent which binds to said receptor; and a second functional unit, comprising a response element corresponding to said receptor, a promoter, a nucleic acid cassette, and a eukaryotic 3'UTR and/or a eukaryotic 3'NCR; wherein said 3'UTR and/or said 3'NCR provides said MRNA stability; wherein said first functional unit expresses said receptor, said receptor forms an interaction between said response element and said agent which binds to said receptor, said interaction regulates the expression of said nucleic acid cassette. 18. The vector of claim 17 wherein said first functional unit and said second functional unit are in the same vector. 19. The vector of claim 17, wherein said first functional unit and said second functional unit are in separate vectors. 20. The vector of claim 17, wherein said receptor is selected from the group consisting of vitamin, steroid, thyroid, orphan, hormone, retinoic acid, thyroxine or GAL4 receptors. 21. The vector of claim 17, wherein said receptor is a Vitamin D receptor, said response element is a Vitamin D response element and said agent is Vitamin D. 22. A cell transformed with a vector for expression of a nucleic acid sequence in tissue, comprising: a nucleic acid cassette; a 5' flanking region including necessary sequences for expression of a nucleic acid cassette; a linker connecting said 5' flanking region to a nucleic acid, said linker having a position for inserting said nucleic acid cassette, wherein said linker lacks the coding sequence of a gene with which it is naturally associated; and a 3' flanking region including a eukaroytic 3' UTR and/or a eukaroytic 3' NCR which stabilizes MRNA expressed from said nucleic acid cassette, wherein said 3' flanking region is 3' to said position for inserting said nucleic acid cassette. 23. The transformed cell of claim 22, wherein said cell is myogenic. 24. A method for transfection of a cell in situ comprising the step of contacting said cell with a vector for sufficient time to transfect said cell, wherein said vector comprises: a nucleic acid cassette; a 5' flanking region including necessary sequences for expression of a nucleic acid cassette; a linker connecting said 5' flanking region to a nucleic acid, said linker having a position for inserting said nucleic acid cassette, wherein said linker lacks the coding sequence of a gene with which it is naturally associated; and a 3' flanking region including a eukaroytic 3' UTR and/or a eukaryotic 3' NCR which stabilizes MRNA expressed from said nucleic acid cassette, wherein said 3' flanking region is 3' to said position for inserting said nucleic acid cassette. 25. The method of claim 24, wherein transfection of said cell is in vivo. 26. The method of claim 24, wherein transfection of said cell is ex vivo, further comprising the steps of cotransfecting said vector with a selectable marker and selecting the transformed cells.

Details for Patent 5,756,264

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2015-05-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2015-05-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2015-05-26